25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
As we previously reported, the New York State Senate and Assembly passed an omnibus bill that overha...
Read More >
We encounter this scenario a lot: a company executive preparing contracts for key employees, or cons...
Read More >
The Internal Revenue Service recently announced its cost-of-living adjustments applicable to dollar ...
Read More >
Seyfarth Synopsis: On February 18, 2020, Governor Phil Murphy announced proposed legislation amendin...
Read More >
Channel Medsystems, Inc. v. Boston Scientific Corp., C.A. No. 2018-0673-AGB (Del. Ch. Dec. 18, 2019)...
Read More >
This week, in response to the emergence of COVID-19 hot spots in downstate New York, Governor Cuomo ...
Read More >